Atogepant Patent Expiration

Atogepant is Used for preventing migraine attacks in adults. It was first introduced by Abbvie Inc in its drug Qulipta on Sep 28, 2021.


Atogepant Patents

Given below is the list of patents protecting Atogepant, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Qulipta US10117836 Tablet formulation for CGRP active compounds Jan 30, 2035 Abbvie
Qulipta US8754096 Piperidinone carboxamide azaindane CGRP receptor antagonists Jul 19, 2032 Abbvie
Qulipta US9499545 Piperidinone carboxamide azaindane CGRP receptor antagonists Nov 10, 2031 Abbvie
Qulipta US9850246 Process for making CGRP receptor antagonists Mar 13, 2033 Abbvie


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Atogepant's patents.

Given below is the list recent legal activities going on the following patents of Atogepant.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 11 Apr, 2024 US9499545
transaction for FDA Determination of Regulatory Review Period 14 Feb, 2024 US9499545
transaction for FDA Determination of Regulatory Review Period 14 Feb, 2024 US8754096
transaction for FDA Determination of Regulatory Review Period 30 Jan, 2024 US8754096
transaction for FDA Determination of Regulatory Review Period 30 Jan, 2024 US9499545
Change in Power of Attorney (May Include Associate POA) 26 May, 2023 US9850246
Email Notification 26 May, 2023 US9499545
Electronic Review 26 May, 2023 US9499545
Change in Power of Attorney (May Include Associate POA) 26 May, 2023 US9499545
Electronic Review 26 May, 2023 US9850246



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳